Cargando…

Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: An immunohistochemical study

BACKGROUND: DNA repair is a major defense mechanism, which contributes to the maintenance of genetic sequence, and minimizes cell death, mutation rates, replication errors, DNA damage persistence and genomic instability. Alterations in the expression levels of proteins participating in DNA repair me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giaginis, Constantinos, Michailidi, Christina, Stolakis, Vasileios, Alexandrou, Paraskevi, Tsourouflis, Gerasimos, Klijanienko, Jerzy, Delladetsima, Ioanna, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2011
Materias:	Basic Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524721/ https://www.ncbi.nlm.nih.gov/pubmed/21358597 http://dx.doi.org/10.12659/MSM.881444

Ejemplares similares

Receptor-Binding Cancer Antigen expressed on SiSo cells (RCAS1) expression in human benign and malignant thyroid lesions
por: Giaginis, Constantinos, et al.
Publicado: (2012)

Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: An immunohistochemical study
por: Karidis, Nikolaos P., et al.
Publicado: (2011)

RCAS1 expression in mobile tongue squamous cell carcinoma: An immunohistochemical study
por: Theocharis, Stamatios, et al.
Publicado: (2011)

Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions
por: Lakiotaki, Eleftheria, et al.
Publicado: (2015)

High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma
por: Theocharis, Stamatios, et al.
Publicado: (2021)

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer
por: Nikas, Ilias, et al.
Publicado: (2022)

Increased RCAS1 Expression Is Associated with Advanced Histopathological Stage and Poor Prognosis in Patients with Gastric Adenocarcinoma
por: Giaginis, Constantinos, et al.
Publicado: (2013)

Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors
por: Pouloudi, Despoina, et al.
Publicado: (2021)

Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2014)

An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
por: Javeed, Saira, et al.
Publicado: (2022)

MSH2 and MLH1 testing
por: Kurzawski, Grzegorz, et al.
Publicado: (2008)

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
por: Goutas, Dimitrios, et al.
Publicado: (2021)

Mismatch Repair Proteins and Microsatellite Instability in Colorectal Carcinoma (MLH1, MSH2, MSH6 and PMS2): Histopathological and Immunohistochemical Study
por: Ismael, Nour El Hoda S., et al.
Publicado: (2017)

Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions
por: Cooper, W A, et al.
Publicado: (2008)

The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers
por: Lawes, D A, et al.
Publicado: (2005)

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
por: Georgantzoglou, Natalia, et al.
Publicado: (2021)

Hepatocyte Turnover in Chronic HCV-Induced Liver Injury and Cirrhosis
por: Karidis, Nikolaos P., et al.
Publicado: (2015)

Mlh1 interacts with both Msh2 and Msh6 for recruitment during mismatch repair
por: DuPrie, Matthew L., et al.
Publicado: (2022)

Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer
por: Kassem, H Sh, et al.
Publicado: (2001)

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
por: Micko, Alexander S. G., et al.
Publicado: (2017)

Hepatic encephalopathy: An updated approach from pathogenesis to treatment
por: Toris, Giannakis T., et al.
Publicado: (2011)

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management
por: Psilopatis, Iason, et al.
Publicado: (2022)

Functional examination of MLH1, MSH2, and MSH6 intronic mutations identified in Danish colorectal cancer patients
por: Petersen, Sanne M, et al.
Publicado: (2013)

Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients
por: Rashid, Muhammad Usman, et al.
Publicado: (2019)

The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia
por: Pergaris, Alexandros, et al.
Publicado: (2023)

Clinical and Molecular Insights of Radiation-Induced Breast Sarcomas: Is There Hope on the Horizon for Effective Treatment of This Aggressive Disease?
por: Kokkali, Stefania, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

Population carrier frequency of hMSH2 and hMLH1 mutations
por: Dunlop, M G, et al.
Publicado: (2000)

Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer
por: Haron, Nor Hasyimah, et al.
Publicado: (2019)

UMD-MLH1/MSH2/MSH6 databases: description and analysis of genetic variations in French Lynch syndrome families
por: Grandval, Philippe, et al.
Publicado: (2013)

Alkylation induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins
por: Bugni, James M., et al.
Publicado: (2008)

Mlh1 Can Function in Antibody Class Switch Recombination Independently of Msh2
por: Schrader, Carol E., et al.
Publicado: (2003)

Substantial unexplained variation in cancer risks for MLH1 and MSH2 mutation carriers
por: Dowty, JG, et al.
Publicado: (2012)

Novel Mutations in MLH1 and MSH2 Genes in Mexican Patients with Lynch Syndrome
por: Moreno-Ortiz, Jose Miguel, et al.
Publicado: (2016)

Expression of hMLH1 and hMSH2 proteins in ameloblastomas and tooth germs
por: Bologna-Molina, Ronell, et al.
Publicado: (2018)

Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management
por: Ramsoekh, Dewkoemar, et al.
Publicado: (2009)

Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome
por: Schneider, Nayê Balzan, et al.
Publicado: (2018)

Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma
por: Santos, Juliana Carvalho, et al.
Publicado: (2013)

Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms
por: Bosch, Dustin E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_375dagmjl46fgoa1j74klr4nfr